Long‐term efficacy of xamoterol (a beta 1‐adrenoceptor partial agonist) in patients with mild to moderate heart failure.

Abstract

This study was designed to assess the efficacy of xamoterol in 14 patients with mild to moderate heart failure over a period of 18 months. A beneficial effect on exercise capacity and a lowering of heart rate on exercise was sustained, and ejection fraction did not change, although some deterioration may be expected over this length of time in patients with heart failure. Xamoterol is safe and effective, and its benefits are maintained over at least 18 months.

Predominantβ-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy

“…Xamoterot has been demonstrated to improve cardiac function, symptoms and exercise tolerance after long-term administration to patients with mild to moderate heart failure [5][6][7][8][9]. In those studies the efficacy was attributed to the mild cardiotonic effect mediated by the fll-adrenoceptor stimulating action at low sympathetic activities.…”